MedPath

A double blind randomized study on the effectiveness of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in dark irided hypermetropic childre

Completed
Conditions
Eye strenght. Refraction
10047518
Registration Number
NL-OMON30949
Lead Sponsor
Medisch Centrum Haaglanden
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
45
Inclusion Criteria

Healthy; not suffering from syndromes or diseases, 3 to 6 years (not attending group three of Dutch primary school system) old very dark irided hypermetropic children, possesing good accommodation, with no glasses prior or who did not wear their hypermetropic glasses since at least 4 weeks and able to fixate with each eye.

Exclusion Criteria

All children not possesing the inclusioncriteria (D4a)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Primary outcome parameter is the refractive outcome. Differences will be<br /><br>considered statistical significant if p<0.05. A difference in refractive<br /><br>outcome of > 0.25 D will be considered clinical significant.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary outcomes are amount of cycloplegia and time to reach optimal<br /><br>refractive outcome and amount of cycloplegia. Differences will be considered<br /><br>statistical significant if p<0.05. A difference in amount of accommodation of ><br /><br>0.25 D and a difference in time to optimal refractive outcome and/or maximum<br /><br>cycloplegia of >10 minutes will be considered clinical significant.</p><br>
© Copyright 2025. All Rights Reserved by MedPath